Cargando…

Phenome‐Wide Association Study of Autoantibodies to Citrullinated and Noncitrullinated Epitopes in Rheumatoid Arthritis

OBJECTIVE: Patients with rheumatoid arthritis (RA) develop autoantibodies against a spectrum of antigens, but the clinical significance of these autoantibodies is unclear. Using a phenome‐wide association study (PheWAS) approach, we examined the association between autoantibodies and clinical subphe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Katherine P., Sparks, Jeffrey A., Hejblum, Boris P., Kuo, I‐Hsin, Cui, Jing, Lahey, Lauren J., Cagan, Andrew, Gainer, Vivian S., Liu, Weidong, Cai, T. Tony, Sokolove, Jeremy, Cai, Tianxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378622/ https://www.ncbi.nlm.nih.gov/pubmed/27792870 http://dx.doi.org/10.1002/art.39974

Ejemplares similares

Role of Anti–Carbamylated Protein Antibodies Compared to Anti–Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First‐Degree Relatives, and Healthy Controls
por: Koppejan, H., et al.
Publicado: (2016)

Citrullinated Inhibitor of DNA Binding 1 Is a Novel Autoantigen in Rheumatoid Arthritis
por: Ohara, Ray A., et al.
Publicado: (2019)

Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis
por: Catrina, Anca, et al.
Publicado: (2021)

Peptidylarginine Deiminase Autoimmunity and the Development of Anti–Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten–Carrier Model
por: Auger, Isabelle, et al.
Publicado: (2020)

Antibodies against citrullinated proteins of IgA isotype are associated with progression to rheumatoid arthritis in individuals at-risk
por: Sokolova, Maria V, et al.
Publicado: (2023)

Is Anti–Citrullinated Protein Antibody–Positive Rheumatoid Arthritis Still a More Severe Disease Than Anti–Citrullinated Protein Antibody–Negative Rheumatoid Arthritis? A Longitudinal Cohort Study in Rheumatoid Arthritis Patients Diagnosed From 2000 Onward
por: Boer, Aleid C., et al.
Publicado: (2018)

Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor
por: Hammer, Hilde Berner, et al.
Publicado: (2019)

Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results
por: Van Hoovels, Lieve, et al.
Publicado: (2022)

Association of Sputum Neutrophil Extracellular Trap Subsets With IgA Anti–Citrullinated Protein Antibodies in Subjects at Risk for Rheumatoid Arthritis
por: Okamoto, Yuko, et al.
Publicado: (2021)

Replication of Associations of Genetic Loci Outside the HLA Region With Susceptibility to Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis
por: Viatte, Sebastien, et al.
Publicado: (2016)

N‐Linked Glycans in the Variable Domain of IgG Anti–Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis
por: Hafkenscheid, Lise, et al.
Publicado: (2019)

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis
por: Amkreutz, Josephine A. M. P., et al.
Publicado: (2021)

Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid
por: Spengler, Julia, et al.
Publicado: (2015)

Differences in the Spectrum of Anti–Citrullinated Protein Antibody Fine Specificities Between Malaysian and Swedish Patients With Rheumatoid Arthritis: Implications for Disease Pathogenesis
por: Too, Chun Lai, et al.
Publicado: (2016)

Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study
por: Boman, Antonia, et al.
Publicado: (2019)

Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking
por: Chatzidionysiou, Katerina, et al.
Publicado: (2022)

Association of Distinct Fine Specificities of Anti−Citrullinated Peptide Antibodies With Elevated Immune Responses to Prevotella intermedia in a Subgroup of Patients With Rheumatoid Arthritis and Periodontitis
por: Schwenzer, Anja, et al.
Publicado: (2017)

Combination of Two Monoclonal Anti–Citrullinated Protein Antibodies Induced Tenosynovitis, Pain, and Bone Loss in Mice in a Peptidyl Arginine Deiminase‐4–Dependent Manner
por: Krishnamurthy, Akilan, et al.
Publicado: (2022)

Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
por: Ponchel, Frederique, et al.
Publicado: (2022)

IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross‐Sectional Study Encompassing ~1,500 Samples
por: Kissel, Theresa, et al.
Publicado: (2022)

Low prevalence of anti-SSA (anti-Ro) and anti-SSB (anti-La) autoantibodies in female patients with rheumatoid arthritis with a wish to conceive
por: Smeele, Hieronymus T W, et al.
Publicado: (2021)

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study
por: Alten, Rieke, et al.
Publicado: (2017)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

Identification of Distinct Disease Activity Trajectories in Methotrexate‐Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty‐Four Months
por: Bykerk, Vivian P., et al.
Publicado: (2021)

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study
por: Emery, Paul, et al.
Publicado: (2019)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
por: Wu, Chun, et al.
Publicado: (2022)

Antibodies to Cartilage Oligomeric Matrix Protein Are Pathogenic in Mice and May Be Clinically Relevant in Rheumatoid Arthritis
por: Ge, Changrong, et al.
Publicado: (2022)

Data‐Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2023)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

High Adherence to System‐Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years
por: Barber, Claire E. H., et al.
Publicado: (2018)

A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
por: Juge, Pierre‐Antoine, et al.
Publicado: (2022)

Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: a nationwide, population-based cohort study in Taiwan
por: Ng, Kooi-Heng, et al.
Publicado: (2022)

Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis
por: Scharbatke, Eva C., et al.
Publicado: (2016)

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set
por: Bykerk, Vivian P, et al.
Publicado: (2016)

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial
por: van Vollenhoven, R. F., et al.
Publicado: (2015)

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
por: Chatzidionysiou, Katerina, et al.
Publicado: (2019)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hdmq99g6qonuneb0u0mmvljnpj